Skip to main content Accessibility help
×
Home

P.023 Eculizumab shows consistent improvements across muscle groups in patients with AChR antibody-positive refractory myasthenia gravis

  • S Larue (a1), R Mantegazza (a2), KP Fujita (a3), F O’Brien (a3) and JF Howard (a4)...

Abstract

Background: The physician-reported Quantitative Myasthenia Gravis (QMG) test was a key efficacy measure in REGAIN, a 26-week, phase 3, placebo-controlled study of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized MG. Ocular and generalized weakness have shown variable responses to therapies including prednisone and intravenous immunoglobulin/plasma exchange. Using the patient-reported MG Activities of Daily Living (MG-ADL) scale during REGAIN, eculizumab showed a consistent trend toward rapid and sustained improvement across bulbar, respiratory, limb and ocular domains. We analyzed the effect of eculizumab on bulbar, respiratory, gross motor and ocular domains during REGAIN, using the QMG test. Methods: QMG domain score changes to REGAIN week 26 were determined for patients with abnormal baseline scores. Repeated-measures analyses were performed for bulbar (swallowing/speech), respiratory (forced vital capacity), gross motor (limb/axial motor items) and ocular (ocular/facial muscles) domains. Results: Eculizumab-treated patients showed improvements in all four QMG domain scores to week 26. Rapid, sustained improvements were demonstrated across all domains, with a trend toward significant differences between eculizumab and placebo (bulbar, p=0.0628; respiratory, p=0.0682; gross motor, p=0.0114; ocular, p=0.0017). The eculizumab safety profile was consistent with previous reports. Conclusions: Eculizumab demonstrated a consistent response across all QMG muscle domains. This aligns with previously reported MG-ADL findings with eculizumab. (NCT01997229).

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      P.023 Eculizumab shows consistent improvements across muscle groups in patients with AChR antibody-positive refractory myasthenia gravis
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      P.023 Eculizumab shows consistent improvements across muscle groups in patients with AChR antibody-positive refractory myasthenia gravis
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      P.023 Eculizumab shows consistent improvements across muscle groups in patients with AChR antibody-positive refractory myasthenia gravis
      Available formats
      ×

Copyright

P.023 Eculizumab shows consistent improvements across muscle groups in patients with AChR antibody-positive refractory myasthenia gravis

  • S Larue (a1), R Mantegazza (a2), KP Fujita (a3), F O’Brien (a3) and JF Howard (a4)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.